1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

neoplastic cells

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

2

Inhibitory Antibodies

6

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99151
    Brentuximab
    1 Publications Verification

    CAC-10

    ADC Antibody TNF Receptor Cancer
    Brentuximab (CAC-10) is a chimeric antibody targeting CD30. Brentuximab is conjugated with Monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107A). Brentuximab can be used for the research of cancer, such as lymphoma .
    Brentuximab
  • HY-N6961
    Lapachol
    3 Publications Verification

    Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite Infection Inflammation/Immunology Cancer
    Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .
    Lapachol
  • HY-N7844

    Benzyladenosine

    Apoptosis Adenosine Receptor Inflammation/Immunology Cancer
    N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma - .
    N6-Benzyladenosine
  • HY-43521

    Target Protein Ligand-Linker Conjugates Btk STAT Inflammation/Immunology Cancer
    Ibrutinib-MPEA is an orally active, blood-brain barrier permeable inhibitor of BTK and STAT5. As a derivative of Ibrutinib (HY-10997) conjugated with a PROTAC linker, Ibrutinib-MPEA allows the synthesis of a series of PROTAC molecules. Ibrutinib-MPEA significantly reduces the proliferation of neoplastic mast cells and primary mastocytoma cells by inducing apoptosis and inhibiting IgE-dependent histamine release. Ibrutinib-MPEA is applicable to the research of canine mast cell tumors, cerebral ischemia/reperfusion injury in diabetic mice, and neuroinflammation-related diseases .
    Ibrutinib-MPEA
  • HY-13072
    Cenisertib
    1 Publications Verification

    AS-703569; R-763

    Aurora Kinase Bcr-Abl Akt STAT FLT3 Cancer
    Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
    Cenisertib
  • HY-P3182

    Endogenous Metabolite Cancer
    NADH oxidase is a cyanide-resistant oxidase located on the plasma membrane of animals and plants, which is regulated by growth factors and hormones. NADH oxidase catalyzes the electron transfer from NADH to oxygen, and its activity is closely related to cell growth. The hormone response of NADH oxidase is attenuated in tumor-transformed cells, and it can serve as an anti-tumor target .
    NADH oxidase
  • HY-W587738

    Apoptosis Cancer
    Viridiflorol is an active natural molecule with anti-cancer effect. Viridiflorol induces anti-neoplastic effects on breast (MCF-7, IC50 = 10 µM), lung (A549, IC50 = 30 µM), and brain (Daoy, IC50 = 0.1 µM) cancer cells through apoptosis. Viridiflorol can be used for breast, lung, and brain cancer research .
    Viridiflorol
  • HY-N3913

    STAT Bcl-2 Family Cancer
    Furowanin A is a flavonoid with anti-neoplastic effects. Furowanin A inhibits STAT3/Mcl-1 axis to suppress proliferation, block cell cycle progression, induce apoptosis and promote autophagy. Furowanin A potently inhibits colorectal cancer (CRC) cells .
    Furowanin A
  • HY-13072R

    AS-703569 (Standard); R-763 (Standard)

    Aurora Kinase Bcr-Abl Akt STAT FLT3 Reference Standards Cancer
    Cenisertib (Standard) is the analytical standard of Cenisertib. This product is intended for research and analytical applications. Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
    Cenisertib (Standard)
  • HY-W011788

    Trt-OH

    Biochemical Assay Reagents Cancer
    Triphenylmethanol is a specific clathrate host for methanol and dimethyl sulphoxide. Triphenylmethanol inhibits neoplastic transformation of cells .
    Triphenylmethanol
  • HY-N6961R

    Reference Standards Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite Infection Inflammation/Immunology Cancer
    Lapachol (Standard) is the analytical standard of Lapachol. This product is intended for research and analytical applications. Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity .
    Lapachol (Standard)
  • HY-129767

    Eukaryotic Initiation Factor (eIF) Cancer
    CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity .
    CMLD012612
  • HY-144438

    Aurora Kinase LIM Kinase (LIMK) Cancer
    Aurora/LIM kinase-IN-1 (Compound F114) is a potent and dual inhibitor of aurora and lim kinase. Aurora kinases and lim kinases are involved in neoplastic cell division and cell motility, respectively. Aurora/LIM kinase-IN-1 inhibits GBM proliferation and invasion. Aurora/LIM kinase-IN-1 is a promising new scaffold for dual aurora/lim kinase inhibitors that may be used in future agent development efforts for GBM, and potentially other cancers .
    Aurora/LIM kinase-IN-1
  • HY-W011788R

    Trt-OH (Standard)

    Reference Standards Biochemical Assay Reagents Cancer
    Triphenylmethanol (Standard)
  • HY-120290

    Histone Acetyltransferase Cancer
    PU141 is a selected pyridoisothiazolone HAT inhibitor. PU141 is selective toward CBP and p300. PU141 induces cellular histone hypoacetylation and inhibits growth of several neoplastic cell lines originating from different tissues. Anticancer activity .
    PU141
  • HY-13072B

    AS-703569 benzoate; R-763 benzoate

    Aurora Kinase Bcr-Abl Akt STAT FLT3 Cancer
    Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia .
    Cenisertib benzoate
  • HY-P992366

    Galectin Tim3 Cancer
    HFB200901 is a galectin LGALS9 inhibitor and immunostimulant that can be used in studies related to pancreatic adenocarcinoma, pancreatic intraepithelial neoplasia, KRAS G12C-mutant colon cancer, and prostate cancer. HFB200901 disrupts the LGALS9/TIM-3 axis, while blocking the internalization and vacuolization of recombinant LGALS9. HFB200901 reduces the proportion of regulatory T cells (Treg) and enhances dendritic cell activation, thereby inducing polyfunctional and memory CD8 + T cell responses. HFB200901 inhibits the progression of pancreatic neoplastic lesions and effectively improves the efficacy of PSMA-based vaccination .
    HFB200901
  • HY-182375A

    LPL Receptor Inflammation/Immunology Cancer
    SLB1122168 free base is a Spinster Homolog 2 (Spns2) inhibitor. SLB1122168 free base inhibits Spns2-mediated sphingosine-1-phosphate (S1P) release with an IC50 of 94 nM. SLB1122168 free base induces lymphopenia in circulating lymphocytes in mice and rats .
    SLB1122168 free base
  • HY-182375

    LPL Receptor Inflammation/Immunology
    (R)-SLB1122168 free base, an isomer of SLB1122168 free base (HY-182375A), is a spinster homolog 2 (SPNS2) inhibitor with an IC50 ≤2 μM .
    (R)-SLB1122168 free base
  • HY-N7844R

    Benzyladenosine (Standard)

    Apoptosis Adenosine Receptor Phytohormone Reference Standards Inflammation/Immunology Cancer
    N6-Benzyladenosine (Standard) (Benzyladenosine (Standard)) is the analytical standard of N6-Benzyladenosine (HY-N7844). This product is intended for research and analytical applications. N6-Benzyladenosine is an adenosine receptor agonist, has a cytoactive activity. N6-Benzyladenosine arrests cell cycle at G0/G1 phase and induces cell apoptosis. N6-Benzyladenosine also exerts inhibitory effect on T. gondii adenosine kinase and glioma - .
    N6-Benzyladenosine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: